Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.

de Luis DA, Diaz Soto G, Izaola O, Romero E

Journal of diabetes and its complications25 Feb 2015Cited by 60 (Europe PMC)

PMID25825013DOI10.1016/j.jdiacomp.2015.02.010PepBankPUB-25825013

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, body mass index fell with liraglutide in patients with both rs6923761 genotypes.
In plain wordsIn overweight adults with type 2 diabetes, body mass index fell with liraglutide in both genotype groups.
Peptide
Liraglutide
Outcome
DecreaseBMI change
Study
n = 90
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
In patients with both genotypes, body mass index (BMI), weight and fat decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501301
02HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, body weight fell with liraglutide in patients with both rs6923761 genotypes.
In plain wordsIn overweight adults with type 2 diabetes, weight fell with liraglutide in both genotype groups.
Peptide
Liraglutide
Outcome
DecreaseWeight change
Study
n = 90
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
In patients with both genotypes, body mass index (BMI), weight and fat decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501302
03HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes, body fat fell with liraglutide in patients with both rs6923761 genotypes.
In plain wordsIn overweight adults with type 2 diabetes, body fat fell with liraglutide in both genotype groups.
Peptide
Liraglutide
Outcome
DecreaseFat mass change
Study
n = 90
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
In patients with both genotypes, body mass index (BMI), weight and fat decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501303
04HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, BMI reduction was greater in variant (A) allele carriers than in GG patients.
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, BMI fell more in carriers of the A allele than in GG patients.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction in A-allele carriers versus GG genotype
Study
n = 90
Comparator
GG genotype
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
The proportion of the mentioned reductions was higher in the variant allele carriers; BMI (-0.59±2.5kg/m(2) vs. -1.69±3.9kg/m(2); P<0.05), weight (-2.78±2.8kg vs. -4.52±4.6kg; P<0.05) and fat mass (-0.59±2.5kg vs. -1.69±3.9kg; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501304
05HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, weight reduction was greater in variant (A) allele carriers than in GG patients.
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, weight fell more in carriers of the A allele than in GG patients.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction in A-allele carriers versus GG genotype
Study
n = 90
Comparator
GG genotype
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
The proportion of the mentioned reductions was higher in the variant allele carriers; BMI (-0.59±2.5kg/m(2) vs. -1.69±3.9kg/m(2); P<0.05), weight (-2.78±2.8kg vs. -4.52±4.6kg; P<0.05) and fat mass (-0.59±2.5kg vs. -1.69±3.9kg; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501305
06HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, weight reduction was greater in A-allele carriers by 2.9kg (95% CI: 0.27-5.64).
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, A-allele carriers lost 2.9kg more weight than GG patients.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction difference, A-allele carriers versus GG
Study
n = 90
Comparator
GG genotype
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Measurements
Difference in weight reduction
2.9 kg
A-allele carriers versus GG
Source sentences
Summary
Weight reduction after liraglutide treatment was greater in the A-allele carriers by 2.9kg (95% CI: 0.27-5.64).
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501306
07HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, fat mass reduction was greater in variant (A) allele carriers than in GG patients.
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, body fat fell more in carriers of the A allele than in GG patients.
Peptide
Liraglutide
Outcome
DecreaseFat mass reduction in A-allele carriers versus GG genotype
Study
n = 90
Comparator
GG genotype
Outcome group
Body weight · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
The proportion of the mentioned reductions was higher in the variant allele carriers; BMI (-0.59±2.5kg/m(2) vs. -1.69±3.9kg/m(2); P<0.05), weight (-2.78±2.8kg vs. -4.52±4.6kg; P<0.05) and fat mass (-0.59±2.5kg vs. -1.69±3.9kg; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501307
08HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, the decrease of basal glucose was similar in both genotypes.
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, basal glucose fell similarly in both genotype groups.
Peptide
Liraglutide
Outcome
DecreaseBasal glucose decrease by genotype
Study
n = 90
Comparator
GG genotype
Outcome group
Glycemic control · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
The decrease of basal glucose, HOMA-R and HbA1c was similar in both genotypes.
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501308
09HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, the decrease of HOMA-R was similar in both genotypes.
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, insulin resistance (HOMA-R) fell similarly in both genotype groups.
Peptide
Liraglutide
Outcome
DecreaseHOMA-R decrease by genotype
Study
n = 90
Comparator
GG genotype
Outcome group
Glycemic control · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
The decrease of basal glucose, HOMA-R and HbA1c was similar in both genotypes.
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501309
10HumanNon-randomized trialEfficacy outcome
In overweight adults with type 2 diabetes treated with liraglutide, the decrease of HbA1c was similar in both genotypes.
In plain wordsIn overweight adults with type 2 diabetes treated with liraglutide, HbA1c fell similarly in both genotype groups.
Peptide
Liraglutide
Outcome
DecreaseHbA1c decrease by genotype
Study
n = 90
Comparator
GG genotype
Outcome group
Glycemic control · Metabolic and weight
Studied dose
progressive dose to 1.8mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
The decrease of basal glucose, HOMA-R and HbA1c was similar in both genotypes.
1 context sentence(design, population, supporting numbers)
Summary · context
A population of 90 patients with diabetes mellitus type 2 and overweight, unable to achieve glycemic control (HbA1c>7%) with metformin alone that require initiation of liraglutide treatment in progressive dose to 1.8mg/day subcutaneously, was analyzed.
Report a problemFND-2582501310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords